Skip to content
Iris Loew-Friedrich, Board of Directors, TransCelerate – Clinical Trial Design

Iris Loew-Friedrich


Prof. Dr. med. Iris Loew-Friedrich is Executive Vice-President and Chief Medical Officer, UCB S.A.. She provides strategic global leadership for project leadership, world-wide clinical development, medical affairs and global regulatory affairs for UCB’s portfolio of pipeline projects and products. 

The mission of Biopharma Development Solutions is to develop patient solutions with proven superior and sustainable value for patients suffering from severe diseases. Dr. Loew-Friedrich also oversees UCB’s Patient Affairs function, which places a strategic focus on better understanding and improving the patient experience in currently underserved medical areas in immunological and neurological diseases. 
Prior to taking on her current role in March 2008, Dr. Loew-Friedrich was UCB’s Global Head of Development, during which time she oversaw clinical development of key neurology and immunology products. From 2001 to 2009, Dr. Loew-Friedrich also served as the head of Global Research and Development for Schwarz Pharma, which UCB moved to acquire in 2006. She was also on the Schwarz Pharma Executive Board. 
Dr. Loew-Friedrich held several medical and R&D roles, including Vice-President and Head of Global Projects at BASF Pharma, Ludwigshafen, Germany; Vice-President, Head of Global Clinical Management, HMR/Aventis, and Therapeutic Area Head Rheumatology and Bone Diseases, Hoechst/HMR, Bridgewater, New Jersey. 
Dr. Loew-Friedrich received her medical license and her PhD from Frankfurt University, Frankfurt, Germany, in 1985. From 1985 to 1992, Dr. Loew- Friedrich was the staff physician at the Department for Internal Medicine at the Frankfurt University Medical School, with sub-specialties in immunology, nephrology, and transplantation medicine. She is board-certified in internal medicine and holds a professorship at Frankfurt University Medical School.